Fluid Retention Associated with Imatinib Treatment in Patients with Gastrointestinal Stromal Tumor: Quantitative Radiologic Assessment and Implications for Management

다국어 초록 (Multilingual Abstract)

We aimed to describe radiologic signs and time-course of imatinib-associated fluid retention (FR) in patients with gastrointestinal stromal tumor (GIST), and its implications for management.
In this Institutional Review Board-approved, retrospective study of 403 patients with GIST treated with imatinib, 15 patients with imaging findings of FR were identified by screening radiology reports, followed by manual confirmation. Subcutaneous edema, ascites, pleural effusion, and pericardial effusion were graded on a four-point scale on CT scans; total score was the sum of these four scores.
The most common radiologic sign of FR was subcutaneous edema (15/15, 100%), followed by ascites (12/15, 80%), pleural effusion (11/15, 73%), and pericardial effusion (6/15, 40%) at the time of maximum FR. Two distinct types of FR were observed: 1) acute/progressive FR, characterized by acute aggravation of FR and rapid improvement aftermanagement, 2) intermittent/steady FR, characterized by occasional or persistent mild FR. Acute/progressive FR always occurred early after drug initiation/dose escalation (median 1.9 month, range 0.3–4.0 months), while intermittent/steady FR occurred at any time. Compared to intermittent/steady FR, acute/progressive FR was severe (median score, 5 vs. 2.5, p = 0.002), and often required drug-cessation/dose-reduction.
Two distinct types (acute/progressive and intermittent/steady FR) of imatinib-associated FR are observed and each type requires different management.

참고문헌 (Reference)

1 Ostro D, "Unusual fluid retention with imatinib therapy for chronic myeloid leukemia" 48 : 195-196, 2007

2 Kim KW, "The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer" 75 : 230-235, 2010

3 Thanopoulou E, "The safety profile of imatinib in CML and GIST: long-term considerations" 86 : 1-12, 2012

4 Masiello D, "The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib" 2 : 46-, 2009

5 Trent JC, "Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate" 116 : 184-192, 2010

6 Verweij J, "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib : randomised trial" 364 : 1127-1134, 2004

7 Marrari A, "Predictors of response to targeted therapies for gastrointestinal stromal tumors" 136 : 483-489, 2012

8 Van Glabbeke M, "Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)" 42 : 2277-2285, 2006

9 Joensuu H, "Practical management of tyrosine kinase inhibitor-associated side effects in GIST" 37 : 75-88, 2011

10 Heuchel R, "Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3’kinase signaling" 96 : 11410-11415, 1999

11 Blanke CD, "Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033" 26 : 626-632, 2008

12 Peng B, "Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients" 22 : 935-942, 2004

13 Figueras J, "Nature and progression of pericardial effusion in patients with a first myocardial infarction : relationship to age and free wall rupture" 144 : 251-258, 2002

14 Pinilla-Ibarz J, "Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia : definitions and clinical implications" 117 : 688-697, 2011

15 Pietras K, "Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors" 61 : 2929-2934, 2001

16 Verweij J, "Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study" 39 : 2006-2011, 2003

17 Verweij J, "Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients : analysis of EORTC-ISG-AGITG study 62005" 43 : 974-978, 2007

18 Siddiqui MA, "Imatinib : a review of its use in the management of gastrointestinal stromal tumours" 67 : 805-820, 2007

19 Hong X, "Gastrointestinal stromal tumor : role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib" 26 : 481-495, 2006

20 Demetri GD, "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors" 347 : 472-480, 2002

21 Kerkelä R, "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate" 12 : 908-916, 2006

22 Trotti A, "CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment" 13 : 176-181, 2003